Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Proceedings of the National Academy of Sciences of the United States of America|May 8, 2007
Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disordersKristine Roy, Joshua C Murtie, Bassem F El-Khodor, et al.
Scientific Reports|February 14, 2020
Cerebrospinal fluid proteomics implicates the granin family in Parkinson's diseaseMelissa S Rotunno, Monica Lane, Wenfei Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 10, 2015
Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosisJames C Dodge, Christopher M Treleaven, Joshua Pacheco, et al.
Research Square|June 17, 2024
Genome-wide association study of glucocerebrosidase activity modifiersEmma N Somerville, Lynne Krohn, Konstanin Senkevich, et al.
Molecular Neurobiology|April 29, 2025
Genome-Wide Association Study of Glucocerebrosidase Activity ModifiersEmma N Somerville, Lynne Krohn, Konstantin Senkevich, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 28, 2012
Gene transfer to the CNS is efficacious in immune-primed mice harboring physiologically relevant titers of anti-AAV antibodiesChristopher M Treleaven, Thomas J Tamsett, Jie Bu, et al.
Human Molecular Genetics|April 30, 2016
Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's diseaseEdward Rockenstein, Jennifer Clarke, Catherine Viel, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 7, 2011
CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathyS Pablo Sardi, Jennifer Clarke, Cathrine Kinnecom, et al.
Brain Communications|November 11, 2021
Viral alpha-synuclein knockdown prevents spreading synucleinopathySindhu Menon, Rikke H Kofoed, Fadl Nabbouh, et al.
The Lancet. Neurology|July 21, 2023
Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trialNir Giladi, Roy N Alcalay, Gary Cutter, et al.
Pageof 5